
HBIO
Harvard Bioscience Inc.
$0.48
+$0.01(+1.71%)
25
Overall
--
Value
25
Tech
--
Quality
Market Cap
$21.59M
Volume
346.82K
52W Range
$0.28 - $2.82
Target Price
$2.00
Order:
Income Statement
Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
Total Revenue | $108.7M | $104.5M | $77.4M | $120.8M | $116.2M | $102.1M | $118.9M | $113.3M | $112.3M | $94.1M | ||
Total Revenue | $108.7M | $104.5M | $77.4M | $120.8M | $116.2M | $102.1M | $118.9M | $113.3M | $112.3M | $94.1M | ||
COST OF GOODS SOLD | ||||||||||||
Cost of Revenue | $-59.9M | $-56.1M | $-38.2M | $-57.6M | $51.9M | $44.1M | $51.3M | $52.5M | $46.2M | $39.4M | ||
GROSS PROFIT | ||||||||||||
Gross Profit | $48.7M | $48.4M | $39.2M | $63.2M | $64.3M | $58.0M | $67.7M | $60.8M | $66.1M | $54.8M | ||
OPERATING EXPENSES | ||||||||||||
Operating Expenses | $-50.4M | $-51.4M | $-39.8M | $-62.2M | $62.4M | $57.8M | $65.6M | $68.0M | $64.2M | $61.0M | ||
Research & Development | $6.4M | $5.4M | $5.6M | $11.0M | $10.7M | $8.7M | $10.8M | $12.3M | $11.8M | $10.4M | ||
Research Expense | $6.4M | $5.4M | $5.6M | $11.0M | $10.7M | $8.7M | $10.8M | $12.3M | $11.8M | $10.4M | ||
Selling, General & Administrative | $40.4M | $41.4M | $32.6M | $45.8M | $46.0M | $43.4M | $48.9M | $49.5M | $46.8M | $43.7M | ||
Selling & Marketing Expenses | $20.6M | $20.5M | $15.1M | $24.4M | $23.3M | $19.9M | $24.6M | $25.0M | $24.1M | $22.2M | ||
General & Administrative Expenses | $19.8M | $20.9M | $17.5M | $21.4M | $22.8M | $23.5M | $24.3M | $24.5M | $22.8M | $21.5M | ||
Salaries & Wages | $-2.8M | $-3.5M | $-3.5M | $-3.0M | $-3.0M | $-215.0K | $349.0K | $-420.0K | $5.0M | -- | ||
Depreciation & Amortization | $2.8M | $2.7M | $1.6M | $5.4M | $5.7M | $5.7M | $5.8M | $6.1M | $5.5M | $5.3M | ||
Depreciation & Amortization | $2.8M | $2.7M | $1.6M | $5.4M | $5.7M | $5.7M | $5.8M | $6.1M | $5.5M | $5.3M | ||
Amortization | $2.8M | $2.7M | $1.6M | $5.4M | $5.7M | $5.7M | $5.8M | $6.1M | $5.5M | $5.3M | ||
Other Operating Expenses | $-50.4M | $-51.4M | $-39.8M | $-62.2M | $-2.1M | $-4.8M | $-176.0K | $-237.0K | $71.0K | $1.6M | ||
OPERATING INCOME | ||||||||||||
Operating income | $-925.0K | $-1.1M | $-635.0K | $984.0K | $1.9M | $221.0K | $2.1M | $-7.2M | $1.9M | $-6.2M | ||
EBITDA | $1.9M | $1.9M | $1.9M | $524.0K | $2.7M | $5.2M | $9.0M | $944.0K | $4.7M | $-4.2M | ||
NON-OPERATING ITEMS | ||||||||||||
Interest Expense (Non-Operating) | $854.0K | $639.0K | $713.0K | $5.4M | -- | $4.8M | $1.5M | $2.5M | $3.6M | -- | ||
Interest Income Operating | $8.0K | $3.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
Intinc | $-1.9M | $135.0K | $-2.0M | $-5.4M | $-5.4M | $-4.8M | $-1.5M | $-2.5M | $-3.6M | $-3.2M | ||
Net Non-Operating Interest Income/Expense | $-854.0K | $-639.0K | $-713.0K | $-5.4M | $-5.4M | $-4.8M | $-1.5M | $-2.5M | $-3.6M | $-3.2M | ||
Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | -- | -- | $-632.0K | $-1.6M | ||
Other Income/Expense | $1.3M | $-1.0M | $739.0K | $3.6M | $469.0K | $2.7M | $666.0K | $535.0K | $859.0K | $2.2M | ||
Other Special Charges | $-1.3M | $-179.0K | $-739.0K | $-3.6M | $-469.0K | $-2.7M | $-666.0K | $302.0K | $-227.0K | $-652.0K | ||
SPECIAL ITEMS | ||||||||||||
Restructring And Mn A Income | $788.0K | $-4.0K | -- | -- | $-1.4M | $2.0M | $1.3M | $2.4M | $391.0K | $835.0K | ||
Special Income Charges | $-788.0K | $-672.0K | $3.6M | -- | $-1.5M | $-2.0M | $-1.3M | $233.0K | $-391.0K | $-835.0K | ||
Impairment of Capital Assets | -- | $676.0K | -- | -- | $1.5M | -- | -- | -- | -- | -- | ||
PRE-TAX INCOME | ||||||||||||
EBIT | $-2.8M | $-2.4M | $-1.9M | $-8.0M | $-5.5M | $-2.5M | $1.4M | $-6.6M | $-2.6M | $-11.7M | ||
Pre-Tax Income | $-3.6M | $-3.1M | $-2.6M | $-8.0M | $-5.5M | $-7.3M | $-140.0K | $-9.2M | $-2.6M | $-11.7M | ||
INCOME TAX | ||||||||||||
Tax Provision | $15.4M | $1.2M | $-605.0K | $-3.7M | $-815.0K | $518.0K | $148.0K | $337.0K | $859.0K | $740.0K | ||
NET INCOME | ||||||||||||
Net Income | $-19.0M | $-1.9M | $-865.0K | $-2.9M | $-4.6M | $-7.8M | $-288.0K | $-9.5M | $-3.4M | $-12.4M | ||
Net Income (Continuing Operations) | $-19.0M | $-1.9M | $-865.0K | $-2.9M | $-4.6M | $-7.8M | $-288.0K | $-9.5M | $-3.4M | $-12.4M | ||
Net Income (Discontinued Operations) | $-19.0M | $-1.9M | $-865.0K | $-2.9M | $-4.6M | $-7.8M | $-288.0K | $-9.5M | $-3.4M | $-12.4M | ||
Net Income (Common Stockholders) | $-19.0M | $-1.9M | $-865.0K | $-2.9M | $-4.6M | $-7.8M | $-288.0K | $-9.5M | $-3.4M | $-12.4M | ||
Normalized Income | -- | -- | -- | -- | -- | -- | $1.2M | -- | -- | $-10.7M | ||
TOTALS | ||||||||||||
Total Expenses | $-110.4M | $-107.5M | $-78.0M | $-119.8M | $114.3M | $101.9M | $116.8M | $120.5M | $110.4M | $100.3M | ||
SHARE & EPS DATA | ||||||||||||
Average Shares Outstanding | $33.6M | $34.2M | $34.8M | $36.5M | $37.8M | $38.6M | $40.3M | $41.4M | $42.4M | $43.5M | ||
Average Shares Outstanding (Diluted) | $33.6M | $34.2M | $34.8M | $36.5M | $37.8M | $38.6M | $40.3M | $41.4M | $42.4M | $43.5M | ||
Shares Outstanding | $34.0M | $34.6M | $35.6M | $37.7M | $38.3M | $39.8M | $41.2M | $42.2M | $43.4M | $44.1M | ||
Basic EPS | $-0.57 | $-0.13 | $-0.02 | $-0.08 | $-0.24 | $-0.20 | $-0.01 | $-0.23 | $-0.08 | $-0.28 | ||
Basic EPS (Continuing Operations) | $-0.57 | -- | $-0.06 | $-0.12 | $-0.24 | $-0.20 | $-0.01 | $-0.23 | $-0.08 | $-0.28 | ||
Diluted EPS | $-0.57 | $-0.13 | $-0.02 | $-0.08 | $-0.24 | $-0.20 | $-0.01 | $-0.23 | $-0.08 | $-0.28 | ||
Diluted EPS (Continuing Operations) | $-0.57 | -- | $-0.06 | $-0.12 | $-0.24 | -- | -- | -- | $-0.08 | $-0.28 | ||
OTHER METRICS | ||||||||||||
Acquisition Expense | -- | -- | -- | $-438.0K | -- | -- | -- | -- | -- | -- | ||
Basic Discontinuous Operations | -- | -- | $0.03 | $0.04 | -- | -- | -- | -- | -- | -- | ||
Diluted Discontinuous Operations | -- | -- | $0.03 | $0.04 | -- | -- | -- | -- | -- | -- | ||
Gain On Sale Of Business | -- | $1.2M | -- | -- | $-228.0K | -- | -- | -- | $403.0K | -- | ||
Gains Loss On Disposal Of Discontinued Operations | -- | -- | $1.2M | $1.4M | -- | -- | -- | -- | -- | -- | ||
Net Income Discontinuous Operations | -- | -- | $1.2M | $1.4M | -- | -- | -- | -- | -- | -- | ||
Non Recurring Operation Expense | -- | -- | -- | -- | -- | -- | -- | $-233.0K | -- | -- | ||
Other Gand A | $19.8M | $20.9M | $17.5M | $21.4M | $22.8M | $23.5M | $24.3M | $24.5M | $22.8M | $21.5M | ||
Other Impairment Of Capital Assets | -- | -- | -- | -- | $-100.0K | -- | -- | -- | -- | -- | ||
Other Write Down | -- | -- | -- | -- | -- | $787.0K | -- | -- | -- | -- | ||
Rent And Landing Fees | $19.8M | $20.9M | $17.5M | $21.4M | -- | -- | -- | -- | -- | -- | ||
Selling Expense | $20.6M | $20.5M | $15.1M | $24.4M | $23.3M | -- | -- | -- | -- | -- | ||
Write Down | -- | $484.0K | $-3.6M | -- | -- | -- | -- | -- | -- | -- | ||
Restruct | $788.0K | $-4.0K | -- | -- | $-1.4M | $2.0M | $1.3M | $2.4M | $391.0K | $835.0K |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | HBIO | $0.48 | +1.7% | 346.82K |
3 | ||||
4 | ||||
5 | ||||
6 |